|
gptkbp:instanceOf
|
synthetic drug
|
|
gptkbp:actsOn
|
gptkb:REV-ERBα
gptkb:REV-ERBβ
|
|
gptkbp:alsoKnownAs
|
SR9009
|
|
gptkbp:bannedIn
|
gptkb:World_Anti-Doping_Agency
|
|
gptkbp:CASNumber
|
1379686-30-2
|
|
gptkbp:category
|
research chemical
performance-enhancing drug
REV-ERB agonist
|
|
gptkbp:chemicalFormula
|
C20H24ClN3O4S
|
|
gptkbp:compatibleWith
|
gptkb:SARM
gptkb:FDA
human use
|
|
gptkbp:developedBy
|
gptkb:The_Scripps_Research_Institute
Thomas Burris
|
|
gptkbp:effect
|
altered circadian rhythm (in animal studies)
increased endurance (in animal studies)
reduced fat mass (in animal studies)
|
|
gptkbp:firstDescribed
|
2012
|
|
gptkbp:hasNo
|
approved medical indications
clinical trials in humans
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Stenabolic
|
|
gptkbp:intendedUse
|
research chemical
|
|
gptkbp:legalStatus
|
not approved for medical use
|
|
gptkbp:mechanismOfAction
|
REV-ERB agonist
|
|
gptkbp:molecularWeight
|
437.94 g/mol
|
|
gptkbp:routeOfAdministration
|
oral (in research)
|
|
gptkbp:sideEffect
|
unknown in humans
|
|
gptkbp:structureType
|
non-steroidal
|
|
gptkbp:usedIn
|
preclinical research
|
|
gptkbp:bfsParent
|
gptkb:SR_90000
gptkb:SR_90001
gptkb:SR_90002
gptkb:SR_90003
gptkb:SR_90005
|
|
gptkbp:bfsLayer
|
8
|